.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Practical Management of Advanced Melanoma: A Case-Based Discussion

EP. 1: The Current Understanding of Biomarkers in Melanoma

December 9th 2016

EP. 2: Case I: Newly Diagnosed BRAF Wild Type Advanced Melanoma

December 9th 2016

EP. 3: Melanoma: Helping Patients Understand Immunotherapy

December 9th 2016

EP. 4: Immunotherapy in Melanoma: Managing Toxicities

December 9th 2016

EP. 5: Case 2: Frontline Decisions in Stage IV BRAF-mutant Melanoma

December 9th 2016

EP. 6: Achieving Durable Responses in Advanced Melanoma

December 9th 2016

EP. 7: Patient Selection in Melanoma: Immunotherapy vs Targeted Therapy

December 9th 2016

EP. 8: Sequencing Decisions and Multidisciplinary Care in Metastatic Melanoma

December 9th 2016

EP. 9: Melanoma: Nuances of BRAF/MEK Combinations in the Front line

December 9th 2016

EP. 10: Case 3: Post-Surgical Recurrent Melanoma

December 9th 2016

EP. 11: Adjuvant Therapy Options in Advanced Melanoma

December 9th 2016

EP. 12: Alternative Adjuvant Approaches in Stage III Melanoma

December 9th 2016

EP. 13: Neoadjuvant Trials in High-risk Melanoma

December 9th 2016

EP. 14: T-VEC Data in the Neoadjuvant Setting in Melanoma

December 9th 2016

EP. 15: Remaining Research Questions in Advanced Melanoma

December 9th 2016

EP. 16: The Future Management of Melanoma

December 9th 2016